1011758-03-4

Basic information

• Product Name: Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate))
• Synonyms: Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate));11-(4-Ethyl-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine;Quetiapine EP Impurity P;11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine;Quetiapine Impurity 8;Quetiapine EP Impurity P Fumarate;Quetiapine N-Ethyl Impurity
• CAS NO: 1011758-03-4
• Molecular Formula: C19H21N3S
• Molecular Weight: 323.45514
• Mol File: 1011758-03-4.mol

Chemical Properties

• Boiling Point: 465.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• PKA: 7.67±0.10(Predicted)
• CAS DataBase Reference: Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate))(CAS DataBase Reference)
• NIST Chemistry Reference: Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate))(1011758-03-4)
• EPA Substance Registry System: Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate))(1011758-03-4)

Safety Data

• Hazardous Substances Data: 1011758-03-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate)) is used as a reference compound for quality control and analytical testing in the pharmaceutical industry. It helps in the identification, quantification, and control of impurities in Quetiapine drug products, ensuring that they meet the required standards for safety, efficacy, and purity.
Used in Research and Development:
In the field of research and development, Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate)) serves as a valuable tool for studying the chemical and pharmacological properties of Quetiapine and its related compounds. It can be used to investigate the mechanisms of action, potential side effects, and interactions with other drugs or biological systems.
Used in Regulatory Compliance:
Quetiapine IMpurity P (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine fuMarate)) is also utilized in the regulatory compliance process, as it is necessary for pharmaceutical companies to demonstrate that their drug products are free from harmful impurities or contain them within acceptable limits. This impurity can be used as a benchmark for setting regulatory standards and guidelines for the manufacture and distribution of Quetiapine-containing medications.

Upstream product

• 74-96-4 ethyl bromide 
• 111974-74-4 N-Dealkyl Quetiapine dihydrochloride 
• 5308-25-8 4-ethylpiperazine 
• 13745-86-3 11-chloro-dibenzo[b,f][1,4]thiazepine 

Relevant articles and documents

Refining method of quetiapine fumarate

The invention provides a refining method of quetiapine hemifumarate. The refining method comprises the following steps: feeding crude quetiapine hemifumarate in a refining solvent, adding certain amount of fumaric acid, performing backflow pulping, cooling, crystallizing, filtering and drying to obtain a finished quetiapine hemifumarate product. Through adding the certain amount of fumaric acid, the refining yield and the refining efficiency can be respectively and effectively increased and improved. The invention further provides an impurity synthesis method.

Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate

In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05-0.15% by reverse-phase HPLC. These impurities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,f][1,4]thiazepine-11-yl-1- piperazinyl]1-2-ethanol (impurity I, desethanol quetiapine), 11-[(N-formyl)-1-piperazinyl]-dibenzo[b,f][1,4]thiazepine (impurity II, N-formyl piperazinyl thiazepine), 2-(2-hydroxy ethoxy)ethyl-2-[2-[4-dibenzo[b,f][1,4] thiazepine-11-piperazinyl-1-carboxylate (impurity III, quetiapine carboxylate), 11-[4-ethyl-1-piperazinyl]dibenzo [b,f][1,4] thiazepine (impurity IV, ethylpiperazinyl thiazepine), 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1- piperazinyl)ethoxy]1-ethyl ethanol [impurity V, ethyl quetiapine), 1,4-bis[dibenzo[b,f][1,4]thiazepine-11-yl] piperazine [impurity VI, bis(dibenzo)piperazine]. The known impurity was an intermediate, 11-piperazinyl-dibenzo [b,f][1,4]thiazepine (piperazinyl thiazepine). The structures were established unambiguously by independent synthesis and co-injection in HPLC to confirm the retention times. To the best of our knowledge, these impurities have not been reported before. Structural elucidation of all impurities by spectral data (1H NMR, 13C NMR, MS and IR), synthesis and formation of these impurities are discussed in detail.